Save time and jump to the most important pieces.
-SEC Filing
SC 13G - NCS Multistage Holdings, Inc. (0001692427) (Subject)
SC 13G/A - NCS Multistage Holdings, Inc. (0001692427) (Subject)
SC 13G/A - NCS Multistage Holdings, Inc. (0001692427) (Subject)
Third Quarter Results Total revenues of $44.0 million, a 15% year-over-year improvement, driven in part by increased international revenuesNet income of $4.1 million and diluted earnings per share of $1.60, compared to $4.4 million and diluted earnings per share of $1.77 one year agoAdjusted EBITDA of $7.1 million, a $0.3 million year-over-year improvementCash flows from operating activities of $2.1 million for the first nine months of 2024; free cash flow less distributions to non-controlling interest of $0.4 million, a $3.3 million improvement over the first nine months of 2023$15.3 million in cash and $8.6 million of total debt as of September 30, 2024 HOUSTON, Oct. 30, 2024 (GLOBE NE
HOUSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. ("NCS" or the "Company") (NASDAQ:NCSM) will host a conference call to discuss its third quarter 2024 results on Thursday, October 31, 2024 at 7:30 a.m. Central Time (8:30 a.m. Eastern Time). NCS will issue its third quarter 2024 earnings release the evening prior to the conference call. The conference call will be available via a live audio webcast. Participants who wish to ask questions may register for the call here to receive the dial-in numbers and unique PIN. If you wish to join the conference call but do not plan to ask questions, you may join the listen-only webcast here. It is recommended that participants
Second Quarter Results Total revenues of $29.7 million, a 17% year-over-year improvement, driven in part by increased international revenues Net loss of $(3.1) million and loss per share of $(1.21) Adjusted EBITDA of $0.9 million, a $3.2 million year-over-year improvement Cash flows from operating activities of $4.1 million for the first half of 2024; free cash flow less distributions to non-controlling interest improved to $3.2 million compared to $(2.0) million for the first half of 2023$18.6 million in cash and $8.9 million of total debt as of June 30, 2024 HOUSTON, July 31, 2024 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. (NASDAQ:NCSM) (the "Company," "NCS," "we" or "us"),
10-Q - NCS Multistage Holdings, Inc. (0001692427) (Filer)
8-K - NCS Multistage Holdings, Inc. (0001692427) (Filer)
10-Q - NCS Multistage Holdings, Inc. (0001692427) (Filer)
HOUSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. (NASDAQ:NCSM) (the "Company," "NCS," "we" or "us") today announced, effective November 3, 2022, its Board of Directors appointed Michael Morrison as Chief Financial Officer and Treasurer. The current Chief Financial Officer, Mr. Ryan Hummer, has been appointed as the Chief Executive Officer, effective November 1, 2022. "NCS is a leader in providing highly engineered products and services to the oil and gas industry," stated Mr. Morrison, incoming Chief Financial Officer of NCS. "I am excited to join the NCS team. I believe there is excellent potential for growth given the talented and passionate people, strong techno
MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces NRx Pharmaceuticals (NASDAQ:NRXP) will appear on the Emerging Growth Conference today in response to multiple requests and investor demand. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Jonathan Javitt, MD, MPH, Founder and Chairman will be discussing its first steps towards acquisition through its HOPE Therapeutics subsidiary of a national network of interventional psychiatry clinics focused on tr
Third Quarter Results Total revenues of $44.0 million, a 15% year-over-year improvement, driven in part by increased international revenuesNet income of $4.1 million and diluted earnings per share of $1.60, compared to $4.4 million and diluted earnings per share of $1.77 one year agoAdjusted EBITDA of $7.1 million, a $0.3 million year-over-year improvementCash flows from operating activities of $2.1 million for the first nine months of 2024; free cash flow less distributions to non-controlling interest of $0.4 million, a $3.3 million improvement over the first nine months of 2023$15.3 million in cash and $8.6 million of total debt as of September 30, 2024 HOUSTON, Oct. 30, 2024 (GLOBE NE
MIAMI, Oct. 30, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsor:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) [email protected]
4 - NCS Multistage Holdings, Inc. (0001692427) (Issuer)
4 - NCS Multistage Holdings, Inc. (0001692427) (Issuer)
4 - NCS Multistage Holdings, Inc. (0001692427) (Issuer)